肿瘤标记物联合检测在肺癌临床诊断中的价值

Evaluation of Clinical Value of Combined Tumor Markers Detection in Diagnosis of Lung Cancer

目的:探讨血清肿瘤标记物癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、细胞角蛋白片段(CYFRA_(21-1)联合检测在肺癌诊断中的价值。方法:用放射免疫法分别检测68例肺癌患者和34例肺良性疾病患者的血清中CEA、NSE、CYFRA_(21-1)水平。结果:CEA在肺腺癌中的水平(37.54±7.24)μg/L,高于肺鳞癌(12.79±8.63)、肺小细胞癌(3.26±1.74)及肺良性病组(2.32±.1.46)(P<0.01);NSE在肺小细胞中水平(26.25±7.88)ng/ml高于肺腙癌(19.54±6.38)、肺鳞癌(16.22±8.02)及肺良性病组(9.24+2.81)(P<0.01);CYFRA_(21-1)在肺鳞癌中的水平为(22.38±8.56)ng/ml高于肺小细胞(8.74±3.21)、肺腺癌(10.82+4.30)及肺良性病组(1.42±0.71)(P<0.01)。三项联合检测肺癌的阳性率为82.35％。结论:CEA、NSE.CYFRA_(21-1)三项指标联合检测可提高肿瘤诊断的阳性率。

Objective:To evaluate clinical value of single or combined tumor marker detection CEA,NSE and CYFRA21-1 in the diagnosis of lung cancer. Methods: the serum level of CEA,NSE and CYFRA21-1 both in 68 lung cancer patients and 34 benign pulmonary diseases patients were measured by radioimmunoassary. Results: CEA leveling lung adenocarcinoma patients was significantly higher than that in squamous cell lung cancer and small cell lung cancer; NSE level in small cell lung cancer patients was significantly higher than that in squamous cell lung cancer and lung adenocarcinoma; CYFRA21-1 in lung squamous cell cancer patients was significantly higher than that in lung adenocarcinoma and small cell lung cancer, Conclusion: the combining measusement of CEA,NSE and CYFRA21-1 is helpful in diagnosis of lung cancer.